Communiqué de presse – 4 Octobre 2024 Gilead annonce que six fabricants de génériques ont obtenu des licencesvolontaires pour produire le lenacapavir, un injectable révolutionnaire pour laprévention et le traitement potentiel du VIH,
Press Statement – 4 October 2024 Today’s announcement by Gilead that six generic manufacturers have been awarded voluntary licenses for the production of lenacapavir—a groundbreaking, twice-yearly injectable for HIV prevention and potential treatment—raises significant
Source : ITPC Global ITPC Global’s reaction to Gilead’s voluntary licence on lenacapravir: Gilead’s announcement of their voluntary license for lenacapavir—a groundbreaking, long-acting HIV prevention method—highlights why we cannot rely on pharmaceutical companies
Source : ITPC Global Despite the world’s efforts, there have been over a million new cases of HIV each year. Lenacapavir (LEN), a long-acting antiretroviral, could change the trajectory of the global HIV
ITPC-MENA is pleased to announce the publication of its latest study, titled « Data Exclusivity under Moroccan Law: Implications for Access to Generic Medicines. » This comprehensive report examines the impact of Morocco’s data exclusivity provisions,
